Evotec Completes Strategic Sale of Just Evotec Biologics Toulouse Biomanufacturing Site to Sandoz to Expand European Biosimilar Capacity
Monday, December 08, 2025
Evotec SE has announced the closing of the previously disclosed transaction to sell its Just Evotec Biologics biomanufacturing site in Toulouse, France, to Sandoz, marking a strategically significant move for both companies within the European biopharma landscape.[3] The deal includes the transfer of the state-of-the-art biologics development and manufacturing facility as well as a license for Sandoz to use Evotec’s continuous manufacturing platform for the development and production of biosimilar molecules.[3] For the European biopharmaceutical industry, this transaction underscores both the intensifying focus on biosimilars as a core strategic growth driver and the increasing importance of advanced, highly efficient manufacturing technologies capable of lowering cost and accelerating time to market. By combining Sandoz’s global leadership in generics and biosimilars with Evotec’s continuous manufacturing expertise, the transaction creates a new anchor asset for biologics development and production in the European Union, with direct implications for supply security, innovation capacity, and competitive dynamics in the region.
Under the agreement, Sandoz acquires the Toulouse facility and gains rights to leverage Evotec’s proprietary continuous biologics manufacturing technology for a portfolio of up to 10 biosimilar programs, with total potential deal value reported at more than US$ 650 million plus royalties linked to commercial performance.[3] The molecules targeted under this framework include six originator products with an estimated combined net sales value of around US$ 90 billion, illustrating the scale of the addressable market and the ambition behind Sandoz’s biosimilar strategy.[3] For European pharma executives and strategists, this signals a reinforced commitment by Sandoz to invest in next-generation manufacturing capabilities within Europe rather than offshoring capacity. It also illustrates a broader sector trend where originator and service-platform companies increasingly collaborate to industrialize continuous bioprocessing as a mainstream modality, moving beyond traditional batch processes to enable higher yields, tighter process control, and more predictable quality at lower cost.
Evotec’s leadership has positioned the transaction as a pivotal step in its transition from being primarily a development and manufacturing operator to becoming a scalable technology and solutions provider for biologics.[3] By exiting direct ownership of the Toulouse plant while retaining and licensing its underlying continuous bioprocessing know-how, Evotec aims to pivot toward a capital-light, high-value model focused on platform technologies and co-owned R&D assets. The company will continue to serve customers in Europe and the United States through its remaining facilities, covering molecular design, upstream and downstream process development, analytical and formulation development, and GMP manufacturing from first-in-human through commercial stages.[3] However, Evotec also plans to expand access to its continuous manufacturing technologies beyond its in-house capacity via a licensing model, effectively disseminating its process innovation across a broader network of partners and clients. For European biotechs and mid-sized pharma, this creates new options to access cutting-edge manufacturing capabilities without the need for heavy capex investments in bricks-and-mortar facilities.
For Sandoz, the acquisition reinforces its strategic objective of building a differentiated global biosimilars platform with robust European manufacturing roots. The Toulouse site enhances Sandoz’s ability to develop and produce monoclonal antibodies and other complex biologics using continuous processing technologies, which can translate into lower cost of goods, increased throughput, and potentially greater flexibility in responding to fluctuating demand. In the context of evolving European healthcare budgets and payer pressure, the ability to offer cost-competitive, high-quality biosimilars is mission-critical. The deal also supports ongoing European policy goals around supply chain resilience and regional manufacturing autonomy, especially for critical biologic therapies. By embedding continuous manufacturing in a European plant, Sandoz can ensure a more efficient and controllable production network, mitigating risks associated with extended global supply chains and single-site dependencies.
From a regulatory and policy perspective, this transaction arrives at a time when European authorities are actively promoting innovation in manufacturing technologies, digitalization of bioprocesses, and robust quality management systems to reinforce the EU’s competitiveness in advanced therapies. Continuous manufacturing aligns closely with these priorities because it offers enhanced process analytical technology integration, real-time release testing opportunities, and improved process robustness. European regulators, including the European Medicines Agency (EMA), have in recent years signaled openness to continuous bioprocessing provided that sponsors can demonstrate consistent quality, control strategies, and comparability. As Sandoz further implements Evotec’s platform in Toulouse, the site is likely to become an important reference point for how large-scale continuous biologics manufacturing can be industrialized within a European regulatory framework, potentially informing future guidelines and best-practice recommendations.
Strategically, the transaction also reflects the ongoing realignment of roles between originator pharma, CDMOs, platform technology specialists, and generics or biosimilar companies across Europe. Evotec, traditionally recognized for its drug discovery and early development platforms, is repositioning itself as a technology enabler with a broad portfolio of over 100 proprietary R&D assets in areas such as oncology, cardiovascular and metabolic diseases, neurology, and immunology, many of them co-owned with partners.[3] The divestment of the Toulouse asset releases capital and management bandwidth for Evotec to double down on high-margin, scalable platforms, including AI-enabled discovery, integrated R&D services, and advanced modality development. At the same time, Sandoz, which has spun off from Novartis as an independent generics and biosimilars champion, is consolidating physical assets that can underpin long-term supply commitments to health systems and payers. This reallocation of capital and capabilities illustrates a maturing European biopharma ecosystem where each segment seeks sharper strategic focus.
For other European stakeholders—biotech innovators, contract manufacturers, technology providers, and supply chain partners—the Evotec–Sandoz deal provides several actionable insights. First, it highlights the rising strategic value of continuous manufacturing IP and the potential of licensing models as a route to monetize process innovation without bearing full operational risk. Second, it demonstrates that high-value, late-stage biosimilar portfolios increasingly depend on integrated development-to-manufacturing solutions that can compress timelines, secure capacity, and ultimately drive competitive pricing. Third, it reinforces the notion that European sites with deep process expertise and skilled workforces remain attractive assets, even in a globalized market, particularly when they are configured for next-generation manufacturing. As pricing and access pressures intensify, more transactions of this type—combining asset transfers, long-term supply frameworks, and technology licenses—are likely to appear across the continent in coming years.
Looking ahead, industry analysts will be watching how quickly Sandoz can scale biosimilar programs through the Toulouse facility under the new operating model, and whether performance metrics such as batch cycle times, cost of goods, and product launch cadence validate the strategic thesis around continuous manufacturing. For Evotec, key questions center on how effectively it can broaden adoption of its continuous platform among additional partners, and how the freed resources will accelerate its broader biologics and small-molecule innovation pipeline. For European regulators and policymakers, the success of this model could serve as a proof of concept for how public–private and cross-company collaborations can foster a resilient, innovation-driven manufacturing base for biologics, supporting both industrial competitiveness and sustainable patient access to advanced therapies across the region.
